Neuregulin1 modulation of experimental autoimmune encephalomyelitis (EAE)

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Neuregulin1 (NRG1) is a key factor in glial development and neuronal function.
• NRG1 antagonists show potential in reducing neuroinflammation and microglial activation.
• Experimental autoimmune encephalomyelitis (EAE) is a model for multiple sclerosis (MS).

Purpose of the Study:

• To investigate the therapeutic potential of a Neuregulin1 (NRG1) antagonist (HBD-S-H4) in the central nervous system (CNS) for experimental autoimmune encephalomyelitis (EAE).
• To determine if CNS expression of HBD-S-H4 impacts disease severity in a mouse model of multiple sclerosis (MS).
• To explore potential sex differences in the therapeutic efficacy of HBD-S-H4 in EAE.

Main Methods:

• Generation of transgenic mice expressing the HBD-S-H4 fusion protein in the CNS.
• Induction of myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE).
• Assessment of disease severity, onset, and correlation with gene expression in male and female transgenic mice compared to wild-type littermates.

Main Results:

• CNS expression of HBD-S-H4 reduced disease severity in both male and female mice compared to wild-type.
• Female double transgenic mice exhibited delayed disease onset and reduced severity in EAE.
• In male mice, HBD-S-H4 expression negatively correlated with disease severity and microglia-associated gene expression.

Conclusions:

• CNS expression of a Neuregulin1 (NRG1) antagonist demonstrates neuroprotective effects in EAE, particularly in females.
• Sex differences in therapeutic response suggest a complex interplay between NRG1, sex hormones, and microglia-mediated inflammation in MS.
• Targeting microglial activation via NRG1 antagonism holds potential for treating MS, with considerations for sex-specific responses.